AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Drug-agnostic Companion Diagnostic for EGFR Gene Mutations

 TOKYO and XIAMEN, April 28, 2026 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved a partial change to the manufacturing and marketing authorization of the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”) in Japan.  Read the full story here:

RG_Press Release (Approval as a Cross-Label Companion Diagnostic for EGFR Gene Mutations)_.

Download • 149KB